Oncopole Claudius Regaud — Sponsor Intelligence | 8 EU Trials

Filter these 8 trials by condition, phase, country and more.

Open in Search →

8 Registered trials

3 Recruiting

5 Completed trials

1 Countries active

14 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase IV

Phase I (Other)

Phase III: 1 Phase II: 3 Phase I/II: 1 Phase IV: 1 Phase I (Other): 2

100%

5 of 5 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top IMPs

AMITRIPTYLINE 1 ARGININE HYDROCHLORIDE, LYSINE HYDROCHLORIDE 1 CAPSAICIN 1 CARBOPLATIN 1 CISPLATIN 1 DACARBAZINE CITRATE 1 DAROLUTAMIDE 1 DOXORUBICIN 1 DURVALUMAB 1 FLUOROURACIL 1 IFOSFAMIDE 1 LUTETIUM (177LU) OXODOTREOTIDE 1

All trials

8 total

Influence des caractéristiques morphologiques sur la pharmacocinétique et la toxicité du trastuzumab-déruxtécan chez des patients ayant un c… Recruiting

2025-522656-68-00 Phase IV 1 country TRASTUZUMAB DERUXTECAN
Reduction in the number of chemotherapy cycles in combination with Pembrolizumab in first-line treatment of PD-L1-positive recurrent or meta… Recruiting

2024-514875-16-00 Phase II 1 country CARBOPLATIN; CISPLATIN; FLUOROURACIL; PEMBROLIZUMAB
Interest of peri operative CHemotherapy In patients with CINSARC highrisk localized Soft Tissue Sarcoma. Recruiting

2024-515384-62-00 Phase III 1 country DACARBAZINE CITRATE; DOXORUBICIN; IFOSFAMIDE
Phase I study evaluating the safety and efficacy of MEDI5752 in combination with stereotactic radiotherapy in patients with metastatic sarco… Ended

2024-515551-38-00 Phase I (Other) 1 country
SUrGery with or without dARolutamide in high-risk and/or locally advanced prostate cancer Ended

2022-501518-67-00 Phase II 1 country DAROLUTAMIDE
A Phase I Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTA0-Tyr3-Octreotate in Children … Ended

2024-515552-21-00 Phase I (Other) 1 country ARGININE HYDROCHLORIDE, LYSINE HYDROCHLORIDE; LUTETIUM (177LU) OXODOTREOTIDE
Phase II Randomized Controlled Study Aiming to Evaluate the Interest of Qutenza in Patients With ORL Cancer in Remission and With Sequellae … Ended

2024-515510-41-00 Phase II 1 country AMITRIPTYLINE; CAPSAICIN
A phase I/II multicenter trial evaluating the association of hypofractionated stereotactic radiation therapy and the anti-PD-L1 Durvalumab (… Ended

2024-515000-39-00 Phase I/II 1 country DURVALUMAB

Showing 1–8 of 8 trials

← All sponsors A–Z